Previous studies have demonstrated the beneficial effects of microfocused ultrasound with visualization (MFU-V) for treating chest wrinkles; however, those studies followed subjects for only 180 days. The objective of the following study was to assess the long-term effects of MFU-V for the treating chest wrinkles. Each subject was treated with 4-4.5 mm, 7-3.0 mm, and 10-1.5 mm transducers. Subjects were subsequently evaluated on post-treatment days 6, 12, 180, and 360. Digital images were obtained of the décolleté area of each subject prior to treatment and at each follow-up evaluation. Wrinkle severity was assessed using the validated Merz Décolletage Wrinkle Scales at each follow-up visit and Subject Satisfaction Questionnaires were completed on post-treatment days 180 and 360. Enrolled subjects (N=20) were female with a mean (SD) age of 54.9 (7.5) years (range, 44 to 71 years). The study was completed by 15 subjects. Subjects achieved a significant decrease in dynamic wrinkle scores over time (P<0.01). Baseline scores were significantly decreased at day 90 (P≤0.01) which remained significant at days 180 and 360 (for each, P<0.01). Subjects also showed significantly decreased at-rest wrinkle scores over time (P≤0.01). Baseline scores were significantly decreased at day 90 (P≤0.01), which remained significant at days 180 and 360 (for each, P=0.01). Mean (SD) subject satisfaction scores increased from 2.9 (1.8) on day 180 to 3.9 (1.8) on day 360.J Drugs Dermatol. 2020;19(11):1026-1029. doi:10.36849/JDD.2020.5265.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.36849/JDD.2020.5265 | DOI Listing |
Background: Surgical aortic valve replacement (SAVR) is the commonly used approach for aortic valve replacement (AVR) in patients with aortic stenosis at low or intermediate surgical risk. However, transcatheter aortic valve replacement (TAVR) has emerged as an alternative to SAVR for AVR. This meta-analysis aims to assess the comparative efficacy and safety of TAVR versus SAVR in low-to-intermediate surgical risk patients by analyzing temporal trends in the outcomes of TAVR and SAVR at various follow-up intervals, providing a more detailed understanding.
View Article and Find Full Text PDFSci Rep
January 2025
ICAR-Indian Institute of Agricultural Biotechnology, Namkum, Ranchi, 834010, India.
The present study investigates the supplemental effects of chia seed oil (CSO) on the growth performance and modulation of intestinal microbiota in Labeo rohita fingerlings. Four diets were formulated with graded levels of CSO: 1.0%, 2.
View Article and Find Full Text PDFNephrol Dial Transplant
January 2025
Division of Nephrology and Hypertension, Rochester, MN, USA.
Background And Hypothesis: Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B-cell maturation antigen (BCMA), and chimeric antigen receptor T-cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy.
View Article and Find Full Text PDFJ Palliat Med
January 2025
Division of General Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Specialty palliative care has been associated with cost savings at the end of life, while patient navigators have been independently associated with cost savings due to screening and treatment early in the course of disease. Evidence is limited regarding patient navigators and cost savings at the end of life. To determine the cost-effectiveness of a lay patient navigator intervention in improving palliative care outcomes for Hispanic persons with serious noncancer illness.
View Article and Find Full Text PDFNeurol Sci
January 2025
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, Rome, 00168, Italy.
Background: Intrathecal baclofen therapy (ITB) is a well-established treatment modality for severe spasticity, but it is burdened by the need for periodic pump refills. The introduction of a new formulation of baclofen with an extended stability of 180 days (Neteka, Nordic Group BV) could decrease the frequency of refills. We aimed at analyzing the clinical and economic impact of Neteka introduction in our outpatient facility.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!